Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety and Efficacy of BriLife (IIBR-100) Vaccine for COVID-19
NCT04608305Phase 2Completed
- Sponsor
- Israel Institute for Biological Research
- Start
- Oct 2020
- Primary completion
- Oct 2022
- Modality
- Viral Vector Vaccines, Fc-Fusion Proteins
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of Brilife in coronavirus disease 2019 (COVID-19) (18 arms), sponsored by Israel Institute for Biological Research. Primary endpoints: Adverse Events and Serious Adverse Events at 365 days and Neutralizing Antibody Titers to SARS-CoV-2. Started Oct 2020; status: completed.
02
Drugs
Brilife
03
Conditions
coronavirus disease 2019 (COVID-19)
Beyond the preview
Go deeper on NCT04608305.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04608305.